Clarithromycin detailed information

Revision as of 15:33, 4 September 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Clarithromycin detailed information
Clinical data
Pregnancy
category
Routes of
administration
oral
ATC code
Pharmacokinetic data
Bioavailability50%
Protein bindinglow binding
Metabolismhepatic
Elimination half-life3-4 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC38H69NO13
Molar mass747.953 g/mol

WikiDoc Resources for Clarithromycin detailed information

Articles

Most recent articles on Clarithromycin detailed information

Most cited articles on Clarithromycin detailed information

Review articles on Clarithromycin detailed information

Articles on Clarithromycin detailed information in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Clarithromycin detailed information

Images of Clarithromycin detailed information

Photos of Clarithromycin detailed information

Podcasts & MP3s on Clarithromycin detailed information

Videos on Clarithromycin detailed information

Evidence Based Medicine

Cochrane Collaboration on Clarithromycin detailed information

Bandolier on Clarithromycin detailed information

TRIP on Clarithromycin detailed information

Clinical Trials

Ongoing Trials on Clarithromycin detailed information at Clinical Trials.gov

Trial results on Clarithromycin detailed information

Clinical Trials on Clarithromycin detailed information at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Clarithromycin detailed information

NICE Guidance on Clarithromycin detailed information

NHS PRODIGY Guidance

FDA on Clarithromycin detailed information

CDC on Clarithromycin detailed information

Books

Books on Clarithromycin detailed information

News

Clarithromycin detailed information in the news

Be alerted to news on Clarithromycin detailed information

News trends on Clarithromycin detailed information

Commentary

Blogs on Clarithromycin detailed information

Definitions

Definitions of Clarithromycin detailed information

Patient Resources / Community

Patient resources on Clarithromycin detailed information

Discussion groups on Clarithromycin detailed information

Patient Handouts on Clarithromycin detailed information

Directions to Hospitals Treating Clarithromycin detailed information

Risk calculators and risk factors for Clarithromycin detailed information

Healthcare Provider Resources

Symptoms of Clarithromycin detailed information

Causes & Risk Factors for Clarithromycin detailed information

Diagnostic studies for Clarithromycin detailed information

Treatment of Clarithromycin detailed information

Continuing Medical Education (CME)

CME Programs on Clarithromycin detailed information

International

Clarithromycin detailed information en Espanol

Clarithromycin detailed information en Francais

Business

Clarithromycin detailed information in the Marketplace

Patents on Clarithromycin detailed information

Experimental / Informatics

List of terms related to Clarithromycin detailed information

Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydia pneumoniae or TWAR), skin and skin structure infections, and, in HIV and AIDS patients to prevent, and to treat, disseminated Mycobacterium avium complex (MAC). In addition, it is sometimes used to treat Legionellosis Clarithromycin is available under several brand names, for example Biaxin, Klaricid, Claripen and Claridar.

History

Clarithromycin was invented by scientists at the Japanese drug company Taisho Pharmaceutical in the 1970s. The product emerged through efforts to develop a version of the antibiotic erythromycin that did not experience acid instability in the digestive tract and thereby cause side effects, such as nausea and stomach ache. Taisho filed for patent protection over its new drug around 1980 and subsequently introduced a branded version of its drug, called Clarith, to the Japanese market in 1991. In 1985 Taisho had partnered with the American company Abbott Laboratories for the international rights, and Abbott also gained FDA approval for Biaxin in October 1991. The drug went generic in Europe in 2004 and in the U.S. in mid-2005.

Potential new uses

The Australian biotechnology company Giaconda is working on a new triple drug therapy for Crohn's disease that combines clarithromycin with rifabutin and clofazimine.


Available forms

Clarithromycin is commonly administered in tablets (Biaxin), extended-release tablets (Biaxin XL), or oral suspension. In the United States generic clarithromycin is available from Andrx, Genpharm, Ivax, Ranbaxy Laboratories, Roxane, Sandoz, Teva and Wockhardt. It is also used as part of a combination therapy to treat Helicobacter pylori. In the Middle East it is available as Claridar, produced by Dar Al Dawa.

Mechanism of action

Clarithromycin prevents bacteria from growing, by interfering with their protein synthesis. Clarithromycin binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Clarithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophila. Besides this bacteriostatic effect, clarithromycin also has bactericidal effect on certain strains such as Haemophilus influenzae, Streptococcus pneumoniae and Neisseria gonorrhoeae.

Pharmacokinetics

Unlike erythromycin, clarithromycin is acid-stable and can therefore be taken orally without being protected from gastric acids. It is readily absorbed, and diffused into most tissues and phagocytes. Due to the high concentration in phagocytes, clarithromycin is actively transported to the site of infection. During active phagocytosis, large concentrations of clarithromycin is released. The concentration of clarithromycin in the tissues can be over 10 times higher than in plasma. Highest concentrations were found in liver and lung tissue.

Metabolism

Clarithromycin has a fairly rapid first-pass hepatic metabolism, that is, it is metabolised by the liver. However, this metabolite, 14-hydroxy clarithromycin is almost twice as active as clarithromycin. The half-life of clarithromycin is about 5 hours and 14-hydroxy clarithromycin's about 7 hours. Clarithromycin's and its metabolites' main routes of elimination are urinary and biliary excretion.

Side effects

Most common side-effects are gastrointestinal: diarrhea, nausea, abdominal pain and vomiting, facial swelling. Less common side-effects include headaches, dizziness/motion sickness, rashes, alteration in senses of smell and taste, including a metallic taste that lasts the entire time one takes it. Dry mouth, anxiety, hallucinations, and nightmares have also been reported. In more serious cases it has been known to cause anaphylactic shock, jaundice, other liver disorders, and kidney problems including kidney failure. Inform your doctor immediately if side effects are extremely bothersome or serious. Clarithromycin may cause false positives on urine drug screens for cocaine.

Special precautions

Allergic reactions can occur with clarithromycin use. People with a history of allergy, asthma, hay fever or hives seem to be more susceptible to these reactions, and it is normally recommended they avoid the use of Clarithromycin. The reaction can be immediate and severe.

Allergic symptoms include wheezing, hives, itching, swelling, spasms in the throat and breathing tubes, swelling of the face and neck, joint and muscle pain, difficulty breathing, fever and skin rashes. Rashes can range in severity, the most serious cases being toxic epidermal necrolysisand Stevens-Johnson syndrome. Nausea and vomiting are not symptoms of an allergic reaction.

Resistance

Many Gram positive microbes quickly develop resistance to clarithromycin after standard courses of treatment, most frequently via acquisition of the erm(B) gene, which confers high-level resistance to all macrolides.[1]

Contraindications

Clarithromycin should be used with caution if the patient has liver or kidney disease, certain heart problems (e.g., QT prolongation or bradycardia), or an electrolyte imbalance (e.g., low potassium or magnesium levels). Many other drugs can interact with clarithromycin, which is why the doctor should be informed of any other drugs the patient is taking concomitantly. Clarithromycin is almost never used in HIV patients due to significant interaction with HIV drugs.

References

  1. Malhotra-Kumar S, Lammens C, Coenen S; et al. (2007). "Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: A randomised, double-blind, placebo-controlled study". Lancet. 369: 482&ndash, 90. doi:10.1016/S0140-6736(07)60235-9. PMID 17292768.

External links

Template:GlycopeptideAntiBio

de:Clarithromycin th:คลาริโทรมัยซิน

Template:WS